Products from Novo Nordisk
- Top pick1#1· Editor's ChoiceEditor's ChoiceBest for CV Risk
FDA-approved semaglutide for chronic weight management
- Average 15% weight loss in clinical trials (STEP 1)
- FDA-approved with extensive safety record
- Weekly dosing
FDA-approvedBrand-nameOnce-weekly injectionGLP-1 receptor agonistInsurance eligibleMost transparent pricing8.3/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 2.4mg - 2Runner-up
Semaglutide approved for type 2 diabetes
- Strong A1C reduction in T2D
- Often covered by insurance for diabetes indication
Off-label useOnce-weekly injectionGLP-1 receptor agonistInsurance eligible8.2/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 1mg - 3Also great
First FDA-approved oral semaglutide for weight loss (Jan 2026)
- First non-injection FDA-approved weight-loss GLP-1
- Same active ingredient as injection Wegovy with strong efficacy data
- Easier psychological adoption for needle-averse patients
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligibleSee review8.1/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 4
Oral semaglutide for type 2 diabetes (FDA-approved 2019)
- First FDA-approved oral GLP-1 (2019) — long real-world safety record
- T2D indication = strong insurance coverage
- No injection
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligibleSee review8.0/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 5
Daily liraglutide for weight loss
- Long FDA approval history (since 2014)
- Pediatric approval (age 12+)
FDA-approvedBrand-nameDaily injectionGLP-1 receptor agonistSee review7.0/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.